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Background: Renal function is an important prognostic factor for patients with acute heart failure syndromes (AHFS). Atrial natriuretic peptide 
(carperitide) is a potent endogenous diuretic and natriuretic substance that has been shown to improve renal function. It has also been reported 
that nicorandil improve renal blood flow in animal model. The present study aimed to evaluate the renal effects of carperitide and nicorandil as 
treatment for AHFS with chronic kidney disease (CKD).
Methods:  There were 157 patients with AHFS (NYHA class 4, eGFR<60 ml/min/1.73 m(2)) who were admitted to Yamada Red Cross Hospital or 
Kansai Medical University Hirakata Hospital between June 2009 and September 2010. Patients with acute coronary syndrome requiring immediate 
intervention, tachycardia induced heart failure, bradycardia requiring pacemaker, cardiogenic shock, end-stage renal failure on dialysis, any diseases 
with limited life-expectancy were excluded and 79 remaining patients were enrolled. Subjects were randomized to receive carperitide (0.025μg/kg/
min: n=43) or nicorandil (200μg/kg as a bolus, followed by 200μg/kg/hr: n=36) in addition to their usual care. When the systolic blood pressure 
(SBP) decreased to 90mmHg or less, each medicine decreased dosage or was discontinued. Besides, it was continued whether being judged that 
AHFS had improved it. Renal damage was defined as more than 25% of creatinine elevation or initiation of dialysis during hospitalization. The 
primary endpoint was the incidence of renal damage one week after admission and at time the symptoms of heart failure improved.
Results: At baseline, there were no significant differences between the two groups in age, sex, ejection fraction, underlying heart disease, SBP, heart 
rate, serum creatinine, concomitant medications. The incidence of renal damage was significantly lower in the carperitide group (4.7% vs 30.6%, 
p=0.0014). By multivariate logistic regression analysis, use of carperitide was negative predictors of renal damage. (Odds Ratio 0.09, 95% CI -4.30 - 
-0.86, p=0.0012).
Conclusions: In this study, carperitide had better impact on renal function in treatment of AHFS with CKD compared with nicorandil.
